Jan 29 (Reuters) - Botanix Pharmaceuticals Ltd:
* ‍ PHASE 1B STUDY OF BTX 1503 IN PATIENTS WITH MODERATE TO SEVERE ACNE MET ALL DESIGNATED ENDPOINTS ​ Source text for Eikon: Further company coverage:
 